|Articles|February 12, 2021

Moderna Given Greenlight to Increase Vaccine Supply in Vials

Author(s)Killian Meara

Decision comes as Biden states all Americans won’t be vaccinated by the end of summer.

At its current pace, the United Sates is vaccinating about 1.3 million people per day with coronavirus disease 2019 (COVID-19) vaccines. So far, nearly 30 million people have received at least 1 dose, that equals around 10% of the country’s total population. While these numbers are steadily increasing, the rollout is still not where it needs to be, and ways to increase administration are being pursued.

Now, the US Food and Drug Administration (FDA) has announced that they will allow Moderna to increase the amount of vaccine that they put in their vials by 40%. This will allow the company to up the number of doses from 10 to 14 in each vial.

The hopes are that this will allow the stock of vaccines to increase much faster than initially anticipated, getting more doses to more people who need them. However, the FDA still wants Moderna to submit data that shows an immediate 20% increase in each vial will not compromise the vaccine.

“It would be a great step forward,” Moncef Slaoui, who served as the scientific leader of the Trump administration’s vaccine development program said. “I think it will have an impact in the short term.”

Moderna is currently the second leading provider of COVID-19 vaccines in the US, supplying 48% of the country’s stock, just behind Pfizer who supplies around 52%. Pfizer’s vials only contain 6 doses of their vaccine, but since Moderna’s vials have enough extra space, they requested to be able to put more in.

However, problems from overstuffing the vials can arise. If they are filled too much, the vials can crack and there also needs to be enough room in them to ensure the proper extraction of the final dose. If a vial is punctured, it needs to be used or discarded within 6 hours. This poses an issue to pharmacists who may struggle to extract more doses in that time frame.

Recently, Johnson & Johnson has summitted an EUA request to the FDA, in hopes that their vaccine will be approved for emergency use and can be used to aid in the vaccination program. The company hopes to deliver 100 million doses by the end of June, but their manufacturing is still gearing up.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.